🇺🇸 FDA
Pipeline program

Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G

XPORT-DLBCL-30

Phase 3 small_molecule active

Quick answer

Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) is a Phase 3 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials